Compare PCRX & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | QDEL |
|---|---|---|
| Founded | 2006 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.0M | 1.2B |
| IPO Year | 2010 | 2022 |
| Metric | PCRX | QDEL |
|---|---|---|
| Price | $25.41 | $12.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $30.25 | $28.25 |
| AVG Volume (30 Days) | 642.3K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | 45.35 |
| EPS | ★ 0.19 | N/A |
| Revenue | $541,533,000.00 | ★ $2,730,200,000.00 |
| Revenue This Year | $6.78 | $3.51 |
| Revenue Next Year | $8.54 | $3.86 |
| P/E Ratio | $131.68 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $9.92 |
| 52 Week High | $27.66 | $35.58 |
| Indicator | PCRX | QDEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 29.07 |
| Support Level | $24.61 | $10.39 |
| Resistance Level | $26.94 | $12.85 |
| Average True Range (ATR) | 1.00 | 1.08 |
| MACD | -0.25 | -0.41 |
| Stochastic Oscillator | 18.84 | 13.20 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.